Laboratorios Farmaceuticos Rovi, S.A. (LABFF)
- Previous Close
86.05 - Open
90.61 - Bid --
- Ask --
- Day's Range
65.86 - 65.86 - 52 Week Range
65.86 - 90.61 - Volume
207 - Avg. Volume
0 - Market Cap (intraday)
3.369B - Beta (5Y Monthly) 0.45
- PE Ratio (TTM)
21.04 - EPS (TTM)
3.13 - Earnings Date Jul 29, 2025 - Aug 4, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Jul 14, 2025
- 1y Target Est
--
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express; catheter care under the Fibrilin brand; and Sodium Heparin Rovi. In addition, the company offers contract-manufacturing services comprising compounding, aseptic filling and terminal sterilisation, inspection, installation of safety devices, labelling, packaging, serialisation and aggregation, for different injectable pharmaceutical forms, such as prefilled syringes, vials and cartridges, as well as manufacturing and packaging services for solid products. Its products are used for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
www.rovi.es2,197
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: LABFF
Ver másPerformance Overview: LABFF
Trailing total returns as of 6/6/2025, which may include dividends or other distributions. Benchmark is IBEX 35... (^IBEX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Comparar con: LABFF
Selecciona hasta 4 acciones para analizar empresas similares utilizando métricas clave de rendimiento.
Statistics: LABFF
Ver másValuation Measures
Market Cap
3.22B
Enterprise Value
3.31B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
18.25%
Return on Assets (ttm)
14.32%
Return on Equity (ttm)
24.93%
Revenue (ttm)
767.47M
Net Income Avi to Common (ttm)
140.02M
Diluted EPS (ttm)
3.13
Balance Sheet and Cash Flow
Total Cash (mrq)
29.31M
Total Debt/Equity (mrq)
18.08%
Levered Free Cash Flow (ttm)
47.38M